Home Blog of Signal Transduction Others HER2 An unusual mechanism of ERBB4 in regulating tumor related gene expression

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

An unusual mechanism of ERBB4 in regulating tumor related gene expression

 

ERBB4 is a receptor tyrosine kinase of the epidermal growth factor receptor (EGFR/ERBB) family. Unlike other EGFR family members, ERBB4 regulates target gene expression via releasing a soluble intracellular domain (ICD). Haskins et al. found ERBB4 activated the transcriptional coactivator YAP by binding to its ligand neuregulin 1 (NRG1), to regulate gene expression of cancer cells. The article was published on Sciense Signaling, recently.

 

By undergoing intramembrane proteolysis, ERBB4 releases ICD to the nucleus and cooperates with its coactivator, such as YAP, which is a growth factor of tumor development and progression that can be inhibited by the tumor-suppressor Hippo pathway. NRG1 actives YAP with a similar extent compared with two well known YAP activator, epidermal growth factor (EGF) and lysophosphatidic acid (LPA). The activated YAP increases expression level of target genes, such as CTGF, in cultured mammary epithelial cells or breast cancer cells. In the other way, either knocking down YAP/ERBB4 or inhibiting ERBB4 by lapatinib or erlotinib suppresses the expression of CTGF in the presence of NRG1. The study reveals an unusual mechanism of ERBB4 in gene regulation, and demonstrates the important role of NRG1-ERBB4-YAP signaling pathway in promoting tumor development and progression.

 

Reference:
Sci Signal. 2014 Dec 9;7(355):ra116.

Related Products

Cat.No. Product Name Information
S2111 Lapatinib Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
S1792 Simvastatin Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis.
S2061 Lovastatin Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, used for lowering cholesterol (hypolipidemic agent). Lovastatin triggers autophagy.

Related Targets

HER2 HMG-CoA Reductase Others EGFR